Affiliate disclosure: Some links in this article are affiliate links. If you purchase through them, VitaminsForMen.com may earn a commission at no additional cost to you. This does not influence our research or conclusions. See our How We Review page for full details. MEDVi QUAD is a compounded prescription medication requiring evaluation by a licensed clinician. Compounded medications are not FDA-approved as finished drug products. Prescription approval is not guaranteed. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any prescription treatment.
By VFM Research Desk | Last verified: May 2026
Methodology: This review is based on MEDVi’s published Terms & Conditions (reviewed May 2026), Drug Discovery & Development’s April 8, 2026 intake investigation, publicly accessible FDA warning letter #721455, and verified Trustpilot complaint threads in the public record. No product was independently tested. No payment was received from MEDVi for this review.
Medical review status: This content has not been independently reviewed by a named licensed medical professional. All clinical facts are sourced from FDA prescribing information and publicly available regulatory records as cited. Consult a qualified healthcare provider before making any prescription treatment decision.
Quick Answer: MEDVi QUAD is a compounded prescription ED program combining sildenafil, tadalafil, vardenafil, and apomorphine in a sublingual liquid. It is not FDA-approved as a finished formulation. Apomorphine’s US FDA approval covers Parkinson’s disease — not erectile dysfunction. Pricing is listed inconsistently across MEDVi’s own materials ($119–$199/month). A trade publication documented a hypotension screening gap and static 94% success probability in the intake process in April 2026 — details every affiliate review site has ignored. Here is what the verified record actually shows before you submit your card.
Most MEDVi QUAD coverage in 2026 falls into one of two buckets: fabricated wellness blogs calling a compounded prescription medication a “natural plant-based formula,” and affiliate review sites that copy marketing language, attach invented testimonials, and bury the refund policy in a single sentence. Neither helps anyone make a real decision about a prescription program that auto-renews, charges non-refundable consultation fees upfront, and cannot issue refunds on dispensed medication per its own published terms.
This review works from the verified record. Sources are MEDVi’s own website and Terms & Conditions, a Drug Discovery & Development investigation published April 8, 2026, verified Trustpilot complaint threads, and FDA.gov for warning letter documentation. Where information cannot be confirmed, this article says so rather than filling the gap with plausible-sounding specifics.
What MEDVi QUAD Actually Is
MEDVi QUAD is a compounded prescription medication — meaning the FDA has not reviewed or approved it as a finished drug product before it reaches patients. That classification determines everything else in this evaluation, and it is worth understanding precisely before moving on to anything else.
Compounded medications are prepared by licensed pharmacies using active pharmaceutical ingredients under the direction of a prescribing clinician. This is a legal and regulated category of pharmaceutical practice — but the oversight framework is fundamentally different from the drug approval pathway that applies to commercially manufactured medications like Viagra, Cialis, or Levitra. MEDVi itself is not a pharmacy or healthcare provider. Per its published Terms & Conditions, the company operates as a patient management and telehealth coordination platform connecting users with independent licensed physicians and partner compounding pharmacies.
The practical implication: when MEDVi’s marketing describes QUAD as containing “the active ingredients in Viagra, Cialis, and Levitra,” MEDVi is describing the drug classes involved — but the compounded formulation itself is a different product from any named brand medication and has not undergone FDA review as a finished drug. The ingredient names overlap; clinical equivalence to commercially approved medications does not follow from that overlap. The four-ingredient combination as a finished compounded formulation has not undergone the FDA drug approval process. That is not necessarily a dealbreaker — compounding is how customized prescription combinations are delivered across medicine — but it is information every person making a health decision deserves to see stated clearly, not buried in a terms page.
Who This Is For
MEDVi QUAD is designed for men who have already tried single-ingredient ED medication at optimized doses and found the results inadequate. The clinical rationale behind a multi-ingredient compounded approach is that individual PDE5 inhibitors address vascular blood flow through one mechanism, while apomorphine addresses neurological signaling through a separate dopamine pathway. Men whose ED has both a vascular and a desire-related or neurological component may be candidates for a multi-pathway approach — but that determination belongs to the prescribing clinician, not to a product page or a review article.
The platform model also suits men who prefer telehealth access for this category of treatment. The enrollment process is entirely online, and MEDVi ships in plain, unmarked packaging per its website.
Who This Is NOT For
If you take any nitrate medication in any form, do not use any PDE5 inhibitor — including MEDVi QUAD — without explicit guidance from your cardiologist. All three PDE5 inhibitors in the QUAD formulation share this absolute contraindication per their individual FDA prescribing information. Combining PDE5 inhibitors with nitrates can cause blood pressure to drop to a dangerous and potentially fatal level. Nitrate medications include nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and amyl nitrate (“poppers”). There is no safe dose threshold for this interaction.
Men on alpha-blockers for blood pressure or benign prostatic hyperplasia should disclose this to the evaluating clinician before any PDE5 inhibitor is prescribed. Men with a recent history of stroke, heart attack, unstable angina, or poorly controlled hypertension should pursue an in-person cardiologist consultation before any PDE5 inhibitor, compounded or otherwise. Men with hypotension face a specific consideration discussed in the intake process section below — and a documented gap in MEDVi’s current intake form.
Men who want FDA-approved finished medications with the full clinical trial evidence base should use single-ingredient generic sildenafil or tadalafil through standard telehealth platforms. Those are well-established, lower-cost options covered in the Best ED Telehealth Platforms guide on this site.
The Four Active Ingredients — What the Verified Record Shows
Each ingredient has its own FDA approval history and clinical evidence base. The QUAD combination as a finished compounded product has not been studied in published clinical trials as a combined entity.
Sildenafil is the active compound in Viagra, FDA-approved for erectile dysfunction since 1998. It inhibits the PDE5 enzyme, allowing smooth muscle tissue in penile vasculature to relax and blood flow to increase. Standard oral sildenafil peaks in plasma concentration in 30–60 minutes and lasts approximately 4–6 hours. Absorption is significantly slowed by high-fat meals — one of the clinical rationales for sublingual delivery in the QUAD formulation. Nitrate contraindication is absolute.
Tadalafil is the active compound in Cialis, FDA-approved for the same indication. Its half-life of approximately 17.5 hours produces a response window of up to 36 hours per published prescribing information. At low daily doses (2.5–5mg), it is also approved for continuous use rather than on-demand dosing. It is substantially less affected by food intake than sildenafil. Published side effects include headache, back pain, muscle aches, and indigestion. Nitrate contraindication is absolute.
Vardenafil is the active compound in Levitra, FDA-approved for the same indication. MEDVi’s own published materials describe it as the “rapid onset component” of the QUAD formulation — consistent with its pharmacokinetic profile, though individual response times vary. It carries an additional caution for patients with QT prolongation or those on antiarrhythmic medications. Nitrate contraindication is absolute.
Apomorphine is where this analysis diverges most sharply from what competitor reviews publish. Apomorphine’s US FDA approval covers acute intermittent treatment of “off” episodes in advanced Parkinson’s disease — not erectile dysfunction. It has been studied for arousal-related neurological signaling and was marketed internationally as Uprima for ED in some countries, but that does not constitute a US FDA approval for this use. Its inclusion in QUAD is a clinician-directed compounding decision. Documented side effects include nausea, dizziness, and somnolence.
The clinical rationale for combining apomorphine with three PDE5 inhibitors is that apomorphine works through dopamine receptor pathways in the central nervous system — addressing the neurological and desire-related dimension of erectile function — while the PDE5 inhibitors address the vascular dimension. Whether that combination produces clinically meaningful advantages over optimized single-ingredient therapy for a specific patient is a question for the prescribing clinician, not for a product page.
What We Verified — The Intake Process and What Drug Discovery & Development Found
MEDVi’s telehealth intake is the primary safety mechanism for this prescription program — and a credentialed trade publication documented two specific failures in it in April 2026.
MEDVi’s enrollment process has three steps: complete a health questionnaire online (approximately 3 minutes), receive physician review within 24 hours, and receive discreet shipment if approved. MEDVi states that patients who do not qualify are not charged.
In test runs conducted on April 7, 2026 and published on April 8, Drug Discovery & Development documented the following: First, the intake questionnaire asked whether the user had been “diagnosed with high blood pressure (hypertension) or low blood pressure (hypotension)” — then offered only answer cards for hypertension. A user with low blood pressure had no valid path to accurately complete the form. Second, the intake displayed a “94% success probability” figure that appeared static regardless of what the user entered — the same static figure was documented in MEDVi’s GLP-1 intake as well.
Both findings matter for an honest evaluation. An intake form that cannot accurately capture hypotension — a condition directly relevant to PDE5 inhibitor safety — is a meaningful clinical gap, not a cosmetic one. A static success probability that does not reflect actual user responses is a design decision that misleads users about their individual eligibility. MEDVi had not received a separate FDA enforcement action specifically for QUAD at the time of this report. But both gaps are documented in the public record from a credentialed source, and men evaluating this platform deserve to know they exist before completing their intake.
Verification for this report was completed in May 2026 using the Drug Discovery & Development article (April 8, 2026), MEDVi’s published Terms & Conditions, and publicly accessible Trustpilot complaint threads.
Pricing and What the Terms Actually Say
Pricing is listed inconsistently across MEDVi’s own materials — a discrepancy the VFM Research Desk confirmed directly in May 2026. Some sections display $119/month; others show $179–$199/month. Verify current pricing directly at the official MEDVi website before enrolling. Do not rely on any third-party source, including this article.
What MEDVi’s Terms & Conditions state consistently across all verified source materials:
Consultation fees are non-refundable. Per Section XII: medical consult fees are not subject to or eligible for a refund under any circumstances.
Prescription products are non-returnable and all sales are final. The platform cannot accept returns of prescription products for reuse or resale.
The program auto-renews without notice. Per MEDVi’s Financial Consent: all programs are auto-renewing and you will be automatically charged unless you explicitly request cancellation before your payment processes. There are no refunds or exchanges once processed.
Insurance is not accepted. Affiliated medical professional entities are not contracted with any health insurance plan — commercial, government, Medicare, or Medicaid. Patients are solely responsible for all fees.
The weight-loss refund framework in MEDVi’s terms applies only to that program. No equivalent performance-based refund policy for QUAD is published in any verified source material reviewed for this report. Confirm current refund and cancellation terms directly with MEDVi before providing payment information. Note: The specific cancellation window for the QUAD program is not clearly stated in MEDVi’s published materials as reviewed for this report. The GLP-1 program specifies a 72-hour notice window; whether this applies to QUAD is unconfirmed. Confirm the exact cancellation deadline directly with MEDVi before enrolling.
Trustpilot complaint threads in the public record document cases involving unauthorized charges after claimed cancellation (one user cited a $1,200 charge), prescription substitution without prior consent, and cancellation process failures. These are self-reported individual experiences, but they are in the public record and represent relevant due diligence for any auto-renewing subscription in this category.
The FDA Situation — What Was and Wasn’t About QUAD
The FDA warning letter issued to MEDVi in February 2026 addressed GLP-1 weight loss product marketing — MEDVi QUAD was not referenced in that letter. This distinction matters for an accurate evaluation and most competitors either misstate it or ignore it entirely.
The FDA issued warning letter #721455 to MEDVi, LLC on February 20, 2026. Per the publicly available letter, the FDA cited concerns that MEDVi’s website made false or misleading statements about compounded semaglutide and tirzepatide — GLP-1 weight loss medications. The other negative headlines circulating about MEDVi in early 2026 — advertising investigations by Business Insider and Drug Discovery & Development regarding AI-generated physician personas in Meta ads, and class-action litigation involving a clinical infrastructure partner’s cybersecurity breach — also concern MEDVi’s GLP-1 product line and platform operations broadly. QUAD was not named in any of these publicly documented actions at the time of this report.
That said, MEDVi as a platform is operating under real regulatory and media scrutiny. That context touches everything under its umbrella. Men evaluating QUAD should use it as a prompt for sharper questions — about the specific pharmacy fulfilling the prescription, how to verify the reviewing clinician, and current intake process integrity — rather than dismissing it as irrelevant or using it as a blanket disqualifier.
MEDVi Contact Information
Verified from source materials reviewed May 2026: Email: hello@medvi.org | Phone: +1 (585) 312-4226 | Address: MEDVi, LLC, 131 Continental Dr., Ste 305, Newark, DE 19713
Frequently Asked Questions
Is MEDVi QUAD FDA-approved? No — MEDVi QUAD is a compounded prescription medication and has not gone through the FDA drug approval process as a finished product. Sildenafil, tadalafil, and vardenafil each carry FDA approval for erectile dysfunction as standalone medications. Apomorphine is FDA-approved for Parkinson’s disease “off” episodes only. The QUAD combination as a finished compounded formulation has no FDA approval.
What happened with MEDVi and the FDA? The FDA’s February 2026 warning letter addressed GLP-1 weight loss product marketing — QUAD was not referenced. Drug Discovery & Development separately documented intake UX concerns for QUAD in April 2026: a hypotension answer card gap and a static 94% success probability display. No separate FDA enforcement action for QUAD had been issued at the time of this report.
What does MEDVi QUAD cost in 2026? Pricing is listed inconsistently across MEDVi’s own published materials — $119/month in some sections, $179–$199/month in others. This discrepancy was confirmed by the VFM Research Desk in May 2026. Verify current pricing directly at the official MEDVi website before enrolling.
Does MEDVi QUAD offer a refund? Per MEDVi’s published Terms & Conditions, consultation fees are non-refundable and prescription products cannot be returned. All sales are final. The program auto-renews. No performance-based refund policy for QUAD is published in verified source materials. Confirm directly with MEDVi before enrolling.
Is MEDVi QUAD covered by insurance? No. MEDVi operates as a cash-pay platform outside all insurance networks. HSA/FSA eligibility varies by plan — confirm with your plan administrator before assuming coverage.
What is apomorphine and why is it in MEDVi QUAD? Apomorphine is a dopamine agonist working through central nervous system pathways rather than the vascular PDE5 mechanism. Its US FDA approval covers Parkinson’s disease “off” episodes only — not erectile dysfunction. Its inclusion in QUAD is a clinician-directed compounding decision targeting the neurological arousal dimension alongside the three PDE5 inhibitors.
What did Drug Discovery & Development find about MEDVi’s intake process? In April 7, 2026 test runs, the publication found that MEDVi’s intake offered no valid answer card for hypotension despite asking about it, and displayed a static 94% success probability regardless of user responses. Both findings are documented in the public record from a credentialed trade publication.
Final Assessment
MEDVi QUAD is a real compounded prescription program with a coherent clinical rationale. Three PDE5 inhibitors at different speed and duration profiles combined with apomorphine’s dopamine pathway mechanism addresses multiple dimensions of erectile function that single-ingredient therapy leaves untouched for some men. The sublingual liquid format offers legitimate pharmacokinetic advantages over standard oral tablets for onset speed and food interference. The three-entity telehealth structure — platform, independent physician, licensed pharmacy — is standard in the industry.
What the verified record also shows: apomorphine’s FDA approval history is not what MEDVi’s marketing implies. Pricing is inconsistently published across MEDVi’s own materials. The intake process has two documented UX gaps directly relevant to patient safety screening. Cancellation and refund terms are restrictive and non-negotiable once dispensed. Public complaint records describe specific cases of unauthorized charges and prescription substitution without prior consent.
Men for whom a multi-pathway compounded approach makes clinical sense — who have genuinely exhausted optimized single-ingredient therapy and want to discuss a more comprehensive strategy with a clinician — have reason to evaluate this program carefully. Go in with your complete medication list, current pricing verified directly with MEDVi, Terms reviewed before committing, and the intake UX limitations understood — particularly if you have any history of low blood pressure. Men starting their ED treatment journey should begin with the more established, lower-cost, FDA-approved single-ingredient options covered in the Best ED Telehealth Platforms guide on this site.
For a deeper look at how PDE5 inhibitors work mechanically, read PDE5 Inhibitors Explained. For the full safety profile including nitrate interactions and cardiovascular contraindications, read the ED Medication Safety Guide. For a methodology-disclosed comparison of compounded ED telehealth platforms including QUAD, Rugiet, BraveRx, Ro Sparks, and BlueChew GOLD, read the Compounded ED Telehealth Comparison.
Content Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. MEDVi QUAD is a compounded prescription medication available only through a licensed provider evaluation. Compounded medications are not FDA-approved as finished drug products. The FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. Always consult a qualified healthcare professional before starting any prescription treatment program. Individual results vary. Prescription approval is not guaranteed.
Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, VitaminsForMen.com may earn a commission at no additional cost to you. This does not influence the information presented.
Publisher Statement: VitaminsForMen.com is an independent editorial publication. It is not a healthcare provider, pharmacy, or licensed medical practice. This site has no affiliation with MEDVi, LLC and received no payment from MEDVi for this review. All findings are based on publicly available information as of May 2026.
Pricing Disclaimer: Pricing is based on MEDVi’s published source materials reviewed in May 2026. MEDVi’s own materials show inconsistent pricing figures. Verify all current pricing and terms directly with MEDVi before enrolling.
Leave a Reply